Royalty Pharma SG&A Expenses 2019-2024 | RPRX

Royalty Pharma sg&a expenses for the twelve months ending December 31, 2024 were $0.237B, a 5.24% decline year-over-year.

  • Royalty Pharma annual sg&a expenses for 2024 were $0.237B, a 5.24% decline from 2023.
  • Royalty Pharma annual sg&a expenses for 2023 were $0.25B, a 9.87% increase from 2022.
  • Royalty Pharma annual sg&a expenses for 2022 were $0.227B, a 24.33% increase from 2021.

Royalty Pharma SG&A Expenses 2019-2024 | RPRX

  • Royalty Pharma annual sg&a expenses for 2024 were $0.237B, a 5.24% decline from 2023.
  • Royalty Pharma annual sg&a expenses for 2023 were $0.25B, a 9.87% increase from 2022.
  • Royalty Pharma annual sg&a expenses for 2022 were $0.227B, a 24.33% increase from 2021.
Related Stocks
Company NameMarket
Cap
American Express (AXP)$213.5B
Blackstone (BX)$118.3B
Moody's (MCO)$92.1B
Coinbase Global (COIN)$65.1B
Brookfield Asset Management (BAM)$26.7B
Synchrony Financial (SYF)$24.8B
Orix Corp Ads (IX)$24.7B
Equitable Holdings (EQH)$16.9B
SoFi Technologies (SOFI)$16.9B
BB Seguridade Participacoes SA (BBSEY)$14.2B
Jefferies Financial Group (JEF)$13.8B
Houlihan Lokey (HLI)$12.3B
Globe Life (GL)$10.4B
Daiwa Securities Group (DSEEY)$9.8B
Freedom Holding (FRHC)$9.4B
Brookfield Wealth Solutions (BNT)$8.7B
XP (XP)$8.3B
SouthState (SSB)$7.7B
Upstart Holdings (UPST)$7.4B
StepStone Group (STEP)$7B
Rithm Capital (RITM)$6.2B
Blue Owl Capital (OBDC)$6.1B
Lazard (LAZ)$5.9B
Virtu Financial (VIRT)$5.7B
Euronet Worldwide (EEFT)$4.7B
StoneX Group (SNEX)$4.1B
PJT Partners (PJT)$3.9B
AXOS FINANCIAL, INC (AX)$3.9B
Intercorp Financial Services (IFS)$3.7B
Abrdn (SLFPY)$3.6B